Arthritis Rheumatol:颈动脉超声在银屑病患者心血管危险分层中的价值

2019-06-27 xiangting MedSci原创

颈动脉粥样硬化与未来出现CVE的风险升高相关。将血管成像数据与传统心血管危险因素信息相结合可以提高PsD患者心血管危险分层的准确性。

这项研究旨在评估由颈动脉超声评估的亚临床动脉粥样硬化是否可以预测银屑病患者(PsD)的偶发性心血管事件(CVE),并确定加入影像数据是否可以通过Framingham危险评分(FRS)改善心血管风险预测。

在这项队列分析中,PsD患者在基线时接受颈动脉超声评估。使用颈动脉内膜中层厚度(cIMT)和总斑块面积(TPA)评估动脉粥样硬化的程度。确定了超声评估后出现的偶发性CVE(新的或复发性)。调整FRS后,使用Cox比例风险模型评估颈动脉粥样硬化指标与发生偶发性CVE风险之间的关联。

对559名PsD患者进行了评估,其中23名患者确诊了偶发性CVE。

研究期间计算的首次CVE发生率为每100患者年1.11次(95%0.74,1.67)。单独分析时,控制FRS后,TPA(危险比(HR)3.74,95%置信区间(CI)1.55,8.85;p=0.003)、平均cIMT(HR 1.21,95%CI 1.03,1.42; p=0.02)、最大cIMT(HR 1.11,95%CI 1.01,1.22; p=0.03)和高TPA分类(HR 3.25,95%1.18,8.95,p=0.02)预测了偶发性CVE。

颈动脉粥样硬化与未来出现CVE的风险升高相关。将血管成像数据与传统心血管危险因素信息相结合可以提高PsD患者心血管危险分层的准确性。

原始出处:

Curtis Sobchak. The value of carotid ultrasound in cardiovascular risk stratification in patients with psoriatic disease. Arthritis Rheumatol. 05 June 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1843553, encodeId=af6e184355374, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Tue Oct 15 05:15:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720523, encodeId=de311e205230f, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Mon Oct 14 09:15:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735637, encodeId=05051e3563727, content=<a href='/topic/show?id=54d0100566f2' target=_blank style='color:#2F92EE;'>#颈动脉超声#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100566, encryptionId=54d0100566f2, topicName=颈动脉超声)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=074233925316, createdName=jmtang, createdTime=Tue Aug 13 15:15:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972657, encodeId=3e0119e265709, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Jan 07 01:15:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357221, encodeId=dc43135e221b8, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 29 03:15:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629787, encodeId=fdd41629e87f9, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sat Jun 29 03:15:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1843553, encodeId=af6e184355374, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Tue Oct 15 05:15:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720523, encodeId=de311e205230f, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Mon Oct 14 09:15:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735637, encodeId=05051e3563727, content=<a href='/topic/show?id=54d0100566f2' target=_blank style='color:#2F92EE;'>#颈动脉超声#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100566, encryptionId=54d0100566f2, topicName=颈动脉超声)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=074233925316, createdName=jmtang, createdTime=Tue Aug 13 15:15:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972657, encodeId=3e0119e265709, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Jan 07 01:15:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357221, encodeId=dc43135e221b8, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 29 03:15:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629787, encodeId=fdd41629e87f9, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sat Jun 29 03:15:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1843553, encodeId=af6e184355374, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Tue Oct 15 05:15:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720523, encodeId=de311e205230f, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Mon Oct 14 09:15:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735637, encodeId=05051e3563727, content=<a href='/topic/show?id=54d0100566f2' target=_blank style='color:#2F92EE;'>#颈动脉超声#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100566, encryptionId=54d0100566f2, topicName=颈动脉超声)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=074233925316, createdName=jmtang, createdTime=Tue Aug 13 15:15:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972657, encodeId=3e0119e265709, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Jan 07 01:15:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357221, encodeId=dc43135e221b8, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 29 03:15:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629787, encodeId=fdd41629e87f9, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sat Jun 29 03:15:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1843553, encodeId=af6e184355374, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Tue Oct 15 05:15:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720523, encodeId=de311e205230f, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Mon Oct 14 09:15:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735637, encodeId=05051e3563727, content=<a href='/topic/show?id=54d0100566f2' target=_blank style='color:#2F92EE;'>#颈动脉超声#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100566, encryptionId=54d0100566f2, topicName=颈动脉超声)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=074233925316, createdName=jmtang, createdTime=Tue Aug 13 15:15:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972657, encodeId=3e0119e265709, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Jan 07 01:15:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357221, encodeId=dc43135e221b8, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 29 03:15:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629787, encodeId=fdd41629e87f9, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sat Jun 29 03:15:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1843553, encodeId=af6e184355374, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Tue Oct 15 05:15:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720523, encodeId=de311e205230f, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Mon Oct 14 09:15:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735637, encodeId=05051e3563727, content=<a href='/topic/show?id=54d0100566f2' target=_blank style='color:#2F92EE;'>#颈动脉超声#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100566, encryptionId=54d0100566f2, topicName=颈动脉超声)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=074233925316, createdName=jmtang, createdTime=Tue Aug 13 15:15:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972657, encodeId=3e0119e265709, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Jan 07 01:15:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357221, encodeId=dc43135e221b8, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 29 03:15:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629787, encodeId=fdd41629e87f9, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sat Jun 29 03:15:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
    2019-06-29 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=1843553, encodeId=af6e184355374, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Tue Oct 15 05:15:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720523, encodeId=de311e205230f, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Mon Oct 14 09:15:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735637, encodeId=05051e3563727, content=<a href='/topic/show?id=54d0100566f2' target=_blank style='color:#2F92EE;'>#颈动脉超声#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100566, encryptionId=54d0100566f2, topicName=颈动脉超声)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=074233925316, createdName=jmtang, createdTime=Tue Aug 13 15:15:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972657, encodeId=3e0119e265709, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Jan 07 01:15:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357221, encodeId=dc43135e221b8, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 29 03:15:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629787, encodeId=fdd41629e87f9, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sat Jun 29 03:15:00 CST 2019, time=2019-06-29, status=1, ipAttribution=)]

相关资讯

J Rheumatol:脊柱关节炎的外周表现及其影响

64%的SpA患者有外周表现。银屑病和HLAB27缺失与出现外周症状有关。

欧洲批准AbbVie的白细胞介素23单抗Skyrizi治疗银屑病

AbbVie宣布欧盟委员会(EC)批准其白细胞介素-23(IL-23)单抗Skyrizi(risankizumab),用于治疗中度至重度斑块状银屑病成人患者。

西安杨森宣布国内每三月皮下注射一次治疗银屑病生物制剂喜达诺®上市

2019年6月5日,强生公司在华制药子公司西安杨森制药有限公司今日宣布,全球首个全人源“双靶向”白细胞介素12(IL-12)和白细胞介素23(IL-23)抑制剂喜达诺®(STELARA ®),即乌司奴单抗注射液,已在中国上市。喜达诺®是一款具有创新给药模式——维持期每三个月皮下注射一次的生物制剂,用于治疗对环孢素、甲氨蝶呤(MTX)或PUVA(补骨脂素和紫外线A)等其他系统治疗不应答、有禁忌或无法

诺华的牛皮癣药物IL-17单抗Cosentyx在国内获批上市

中国国家医疗产品管理局(NMPA)批准诺华的IL-17单抗Cosentyx(苏金单抗)用于治疗中度至重度斑块状银屑病的成年患者。Cosentyx是目前在国内第一个获批的IL-17单抗药物,领先于礼来公司的Taltz(ixekizumab)和Bausch Health的Siliq(布罗达单抗),和强生公司Tremfya(guselkumab)。

第24届世界皮肤病学大会:SKYRIZI(risankizumab)保持完整皮肤清洁的全新两年数据

AbbVie是一家以研究为基础的全球生物制药公司,近日宣布,SKYRIZI(risankizumab)保持完整皮肤清洁的最新两年数据。结果显示,大量接受SKYRIZ(risankizumab)治疗的银屑病患者在94.1周时完成了病变皮肤清除。

银屑病治疗药物本维莫德乳膏获批上市

5月31日,国家药监局发布公告称,近期,国家药品监督管理局通过优先审评审批程序批准1类创新药本维莫德乳膏上市,用于局部治疗成人轻至中度稳定性寻常型银屑病。